Sugi Predict

Sugi Predict / Compounds / SCHEMBL535765

SCHEMBL535765

SCHEMBL535765

CCc1sc(N)nc1C(=O)OC

nearest known ligand 0.56

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.56
▸ ALDH1A1 P00352 6/20 0.51
▸ KDM4E B2RXH2 4/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ HPGD P15428 2/20 0.51
▸ HSD17B10 Q99714 2/20 0.51
▸ FBP1 P09467 1/20 0.50
▸ PKM P14618 3/20 0.49
▸ CYP1A2 P05177 1/20 0.49
▸ RCE1 Q9Y256 1/20 0.46
▸ NPSR1 Q6W5P4 1/20 0.45
▸ MAPT P10636 2/20 0.39
▸ COPS5 Q92905 3/20 0.38
▸ NPC1 O15118 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3095838 0.87 FBP1 (0.66) L3MBTL1ALDH1A1KDM4ESMN1; SMN2HPGD
SCHEMBL2442951 0.86 KDM4E (0.51) L3MBTL1ALDH1A1KDM4ESMN1; SMN2HPGD
SCHEMBL31661235 0.85 ALDH1A1 (0.69) L3MBTL1ALDH1A1KDM4ESMN1; SMN2HPGD
SCHEMBL3066792 0.82 KDM4E (0.48) L3MBTL1ALDH1A1KDM4ESMN1; SMN2HPGD
SCHEMBL22774740 0.81 L3MBTL1 (0.57) L3MBTL1ALDH1A1KDM4ESMN1; SMN2HPGD
SCHEMBL1548833 0.81 L3MBTL1 (0.57) L3MBTL1ALDH1A1KDM4ESMN1; SMN2HPGD
SCHEMBL1002345 0.80 COPS5 (0.54) L3MBTL1ALDH1A1KDM4ESMN1; SMN2HPGD
SCHEMBL2400726 0.80 FBP1 (0.48) L3MBTL1ALDH1A1KDM4ESMN1; SMN2HPGD
SCHEMBL535799 0.79 L3MBTL1 (0.56) L3MBTL1ALDH1A1KDM4ESMN1; SMN2HPGD
Bromide SCHEMBL7136559 0.79 COPS5 (0.52) L3MBTL1ALDH1A1KDM4ESMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220153732-A1 PROTEIN SECRETION INHIBITORS ENODIA THERAPEUTICS SAS (FR) 2022-05-19 — — US disclosed
EP-2499127-B1 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2018-09-05 — — EP disclosed
US-20170355689-A1 HEPATITIS C VIRUS INHIBITOR BRISTOL MYERS SQUIBB CO (US) 2017-12-14 — — US disclosed
EP-2601188-B1 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-10-18 — — EP disclosed
US-9776981-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-10-03 — — US disclosed
EP-2328865-B1 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-05-31 — — EP disclosed
EP-2513091-B1 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-04-12 — — EP disclosed
EP-2499132-B1 HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2017-02-15 — — EP disclosed
EP-2499115-B1 PROCESS FOR PREPARING HEPATITIS C VIRUS INHIBITORS BRISTOL MYERS SQUIBB HOLDINGS IRELAND (CH) 2016-07-27 — — EP disclosed
CN-102791693-B Hepatitis c virus inhibitors BRISTOL-MYERS SQUIBB CO. (US) 2016-04-13 — — CN disclosed
WO-2010117704-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-10-14 — — WO disclosed
WO-2010117635-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-10-14 — — WO disclosed
WO-2010117977-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-10-14 — — WO disclosed
US-20100260708-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2010-10-14 — — US disclosed
US-20100249190-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2010-09-30 — — US disclosed
WO-2010096302-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-08-26 — — WO disclosed
US-20100215616-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2010-08-26 — — US disclosed
WO-2010039793-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-04-08 — — WO disclosed
US-20100080772-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2010-04-01 — — US disclosed
US-20100029690-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS ASAHI KASEI PHARMA CORPORATION (JP) 2010-02-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355689-A1 HEPATITIS C VIRUS INHIBITOR HAVCR2, LIPC, PYGL L3MBTL1 3648/4885ALDH1A1 1107/4885KDM4E 3740/4885
US-20100215616-A1 Hepatitis C Virus Inhibitors HAVCR2, PYGL, HCCS L3MBTL1 3763/4885ALDH1A1 1144/4885KDM4E 3857/4885
US-20100249190-A1 Hepatitis C Virus Inhibitors HAVCR2, EIF2AK2, MAVS L3MBTL1 2136/4885ALDH1A1 2120/4885KDM4E 3206/4885
US-20100080772-A1 Hepatitis C Virus Inhibitors HAVCR2, PYGL, HCCS L3MBTL1 3763/4885ALDH1A1 1144/4885KDM4E 3857/4885
US-20220153732-A1 PROTEIN SECRETION INHIBITORS SEC61B, SEC61A1, SEC61G L3MBTL1 4610/4885ALDH1A1 4817/4885KDM4E 4710/4885
US-20100029690-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS PTGER1, PTGS1, PTGER2 L3MBTL1 3350/4885ALDH1A1 164/4885KDM4E 4180/4885
US-20100260708-A1 Hepatitis C Virus Inhibitors HAVCR2, PYGL, HCCS L3MBTL1 3763/4885ALDH1A1 1144/4885KDM4E 3857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.